Related Experiment Video
Updated: May 5, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
[Which treatment options are validated for chronic viral hepatitis?]
C Höner zu Siederdissen1, M P Manns, M Cornberg
1Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Zentrum Innere Medizin, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
Current treatments offer high control or cure for hepatitis B and C. Hepatitis C therapies are rapidly evolving, while hepatitis D remains challenging. Ribavirin shows promise for hepatitis E.
Area of Science:
- Hepatology
- Virology
- Clinical Medicine
Background:
- Chronic viral hepatitis treatments have significantly advanced in the past decade, particularly for hepatitis B and C.
- Evolving therapeutic strategies necessitate updated clinical guidance.
Purpose of the Study:
- To identify scientifically validated and practically applicable treatment options for viral hepatitis.
- To align recommendations with current research and German/European guidelines.
Main Methods:
- Review of current treatment protocols for hepatitis B (nucleos(t)ide analogues, PEG-IFN) and hepatitis C (PEG-IFN, RBV, direct-acting antivirals).
- Consideration of factors influencing treatment efficacy, including genotype, cirrhosis, and prior treatments.
- Evaluation of emerging therapies and their potential impact.
Main Results:
- Hepatitis B and C treatments demonstrate high efficacy for disease control or cure.
- Hepatitis C treatment landscape is undergoing rapid transformation with new direct-acting antivirals.
- Hepatitis D remains difficult to treat, with high relapse rates on PEG-IFN.
- Acute hepatitis E is typically self-limiting, but ribavirin (RBV) shows efficacy in chronic cases, especially in immunocompromised patients.
Conclusions:
- Available therapies offer substantial benefits for hepatitis B and C management.
- Future hepatitis C treatments promise improved outcomes and personalized approaches.
- Hepatitis D co-infection requires further therapeutic development.
- Ribavirin is a potential off-label treatment for hepatitis E.
More Related Videos
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Pancreatitis II: Collaborative Care
Assessment: